- Gross margin expands to 65 percent during first quarter
- Revenue guidance raised to $195-205 million for 2017, from $170-180 million;
- Guidance for completed Cologuard tests increased to at least 470,000 tests, from at least 415,000;
- 10,000 additional providers ordered Cologuard during the first quarter, and insurance coverage expanded to 78 percent.
MADISON, Wis., April 27, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $48.4 million and completed approximately 100,000 Cologuard tests during the quarter ended March 31, 2017. First-quarter 2017 revenues and completed Cologuard test volume grew 226 percent and 150 percent from the same period of 2016, respectively.